Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16011357 | 0.94 | SCN9A (0.56) | SCN9ASCN5ACYP2C9CYP3A4SCN1A | |
| SCHEMBL14920087 | 0.93 | SCN9A (0.55) | SCN9ASCN5ACYP2C9CYP3A4SCN1A | |
| SCHEMBL16011430 | 0.92 | SCN9A (0.61) | SCN9ASCN5ACYP2C9CYP3A4SCN1A | |
| SCHEMBL16011413 | 0.89 | SCN9A (0.51) | SCN9ASCN5ACYP2C9CYP3A4SCN1A | |
| SCHEMBL16011400 | 0.89 | SCN9A (0.56) | SCN9ASCN5ACYP2C9CYP3A4SCN1A | |
| SCHEMBL16011364 | 0.88 | SCN9A (0.48) | SCN9ASCN5ACYP2C9CYP3A4SCN1A | |
| SCHEMBL16021421 | 0.88 | SCN9A (0.53) | SCN9ASCN5ACYP2C9CYP3A4SCN1A | |
| SCHEMBL16021939 | 0.87 | SCN9A (0.53) | SCN9ASCN5ACYP2C9CYP3A4SCN1A | |
| SCHEMBL14920285 | 0.86 | SCN9A (0.48) | SCN9ASCN5ACYP2C9CYP3A4SCN1A | |
| SCHEMBL14921487 | 0.85 | SCN9A (0.46) | SCN9ASCN5ACYP2C9CYP3A4SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773641-B1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| EP-2773641-B1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-9481677-B2 | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9481677-B2 | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9481677-B2 | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9365578-B2 | — | — | 2016-06-14 | — | — | US | disclosed |
| US-9365578-B2 | — | — | 2016-06-14 | — | — | US | disclosed |
| US-9365578-B2 | — | — | 2016-06-14 | — | — | US | disclosed |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| WO-2013064984-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPV3, TRPV2 | SCN9A 40/4885SCN5A 26/4885CYP2C9 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.